Laurus Labs stock has quadrupled in market cap over two years driven by CDMO business growth; analyst flags expensive valuation despite strong earnings outlook

Tue 6 Oct 2026

Market cap growth over two years

more than four times

CDMO business CAGR

33 percent

CDMO share of FY26 revenue

31 percent

Commercial stage CDMO revenue share

55 percent

Expected earnings CAGR next two years

26 percent

Heard on business television between 10:47:10 - 10:50:10 IST.

• CDMO business grew at 33% CAGR over six years and now constitutes 31% of FY26 revenue
• Management said 55% of CDMO revenue comes from commercial stage molecules, rest from phase 3 supplies
• One phase 3 product received global regulatory approval, seen adding earnings visibility
• Company building one-stop platform for antibody drug conjugate programs including payload linker, conjugation and fill-finish
• Analyst Anubhav expects 26% earnings CAGR over next two years but said stock is trading at expensive valuation, advising new investors wait for better entry level

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.